Prevalence and effects of acute myocardial infarction on hospital outcomes among COVID-19 patients.
Journal
Coronary artery disease
ISSN: 1473-5830
Titre abrégé: Coron Artery Dis
Pays: England
ID NLM: 9011445
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
pubmed:
25
10
2023
medline:
25
10
2023
entrez:
25
10
2023
Statut:
ppublish
Résumé
Acute myocardial infarction (AMI) is one of the most lethal complications of COVID-19 hospitalization. In this study, we looked for the occurrence of AMI and its effects on hospital outcomes among COVID-19 patients. Data from the 2020 California State Inpatient Database was used retrospectively. All COVID-19 hospitalizations with age ≥ 18 years were included in the analyses. Adverse hospital outcomes included in-hospital mortality, prolonged length of stay (LOS), vasopressor use, mechanical ventilation, and ICU admission. Prolonged LOS was defined as any hospital LOS ≥ 75th percentile. Multivariate logistic regression analyses were used to understand the strength of associations after adjusting for cofactors. Our analysis had 94 114 COVID-19 hospitalizations, and 1548 (1.6%) had AMI. Mortality (43.2% vs. 10.8%, P < 0.001), prolonged LOS (39.9% vs. 28.2%, P < 0.001), vasopressor use (7.8% vs. 2.1%, P < 0.001), mechanical ventilation (35.0% vs. 9.7%, P < 0.001), and ICU admission (33.0% vs. 9.4%, P < 0.001) were significantly higher among COVID-19 hospitalizations with AMI. The odds of adverse outcomes such as mortality (aOR 3.90, 95% CI: 3.48-4.36), prolonged LOS (aOR 1.23, 95% CI: 1.10-1.37), vasopressor use (aOR 3.71, 95% CI: 3.30-4.17), mechanical ventilation (aOR 2.71, 95% CI: 2.21-3.32), and ICU admission (aOR 3.51, 95% CI: 3.12-3.96) were significantly more among COVID-19 hospitalizations with AMI. Despite the very low prevalence of AMI among COVID-19 hospitalizations, the study showed a substantially greater risk of adverse hospital outcomes and mortality. COVID-19 patients with AMI should be aggressively treated to improve hospital outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Acute myocardial infarction (AMI) is one of the most lethal complications of COVID-19 hospitalization. In this study, we looked for the occurrence of AMI and its effects on hospital outcomes among COVID-19 patients.
METHODS
METHODS
Data from the 2020 California State Inpatient Database was used retrospectively. All COVID-19 hospitalizations with age ≥ 18 years were included in the analyses. Adverse hospital outcomes included in-hospital mortality, prolonged length of stay (LOS), vasopressor use, mechanical ventilation, and ICU admission. Prolonged LOS was defined as any hospital LOS ≥ 75th percentile. Multivariate logistic regression analyses were used to understand the strength of associations after adjusting for cofactors.
RESULTS
RESULTS
Our analysis had 94 114 COVID-19 hospitalizations, and 1548 (1.6%) had AMI. Mortality (43.2% vs. 10.8%, P < 0.001), prolonged LOS (39.9% vs. 28.2%, P < 0.001), vasopressor use (7.8% vs. 2.1%, P < 0.001), mechanical ventilation (35.0% vs. 9.7%, P < 0.001), and ICU admission (33.0% vs. 9.4%, P < 0.001) were significantly higher among COVID-19 hospitalizations with AMI. The odds of adverse outcomes such as mortality (aOR 3.90, 95% CI: 3.48-4.36), prolonged LOS (aOR 1.23, 95% CI: 1.10-1.37), vasopressor use (aOR 3.71, 95% CI: 3.30-4.17), mechanical ventilation (aOR 2.71, 95% CI: 2.21-3.32), and ICU admission (aOR 3.51, 95% CI: 3.12-3.96) were significantly more among COVID-19 hospitalizations with AMI.
CONCLUSION
CONCLUSIONS
Despite the very low prevalence of AMI among COVID-19 hospitalizations, the study showed a substantially greater risk of adverse hospital outcomes and mortality. COVID-19 patients with AMI should be aggressively treated to improve hospital outcomes.
Identifiants
pubmed: 37876241
doi: 10.1097/MCA.0000000000001293
pii: 00019501-990000000-00144
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-43Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
CDC. COVID data tracker [Online]. Centers for Disease Control and Prevention; 2020. https://covid.cdc.gov/covid-data-tracker . [Accessed 28 August 2022].
Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19. Am J Physiol Cell Physiol 2022; 322:C1–C11.
ASE. ASE statement on COVID-19 [Online]. ASE; 2022. https://www.asecho.org/ase-statement-covid-19/ . [Accessed 6 November 2022].
Loffi M, Piccolo R, Regazzoni V, Di Tano G, Moschini L, Robba D, et al. Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection. Open Heart 2020; 7:e001428.
Becerra-Muñoz VM, Núñez-Gil IJ, Eid CM, Garcia Aguado M, Romero R, Huang J, et al. Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19. Age Ageing 2021; 50:326–334.
Garcia S, Albaghdadi MS, Meraj PM, Schmidt C, Garberich R, Jaffer FA, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol 2020; 75:2871–2872.
Welt FG, Shah PB, Aronow HD, Bortnick AE, Henry TD, Sherwood MW, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from the ACC’s Interventional Council and SCAI. J Am Coll Cardiol 2020; 75:2372–2375.
Bavishi C, Bonow RO, Trivedi V, Abbott JD, Messerli FH, Bhatt DL. Acute myocardial injury in patients hospitalized with COVID-19 infection: a review. Prog Cardiovasc Dis 2020; 63:682–689.
Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr 2020; 14:247–250.
Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, Akbari A, Inabadi M, Savardashtaki A, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther 2021; 19:345–357.
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5:811–818.
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020; 5:802–810.
HCUP. US SID overview [Online]. HCUP-US; 2022. https://hcup-us.ahrq.gov/sidoverview.jsp . [Accessed 28 August 2022].
Von Elm E, Altman D, Egger M, Pocock S, GOtzsche PC, Vandenbroucke JP. ). The strengthening the reporting of observational studies in epidemiology [STROBE] statement: guidelines for reporting observational studies. Gac Sanit 2008; 22:144–150.
Bradley SM, Borgerding JA, Wood GB, Maynard C, Fihn SD. Incidence, risk factors, and outcomes associated with in-hospital acute myocardial infarction. JAMA Network Open 2019; 2:e187348–e187348.
Maynard C, Lowy E, Rumsfeld J, Sales AE, Sun H, Kopjar B, et al. The prevalence and outcomes of in-hospital acute myocardial infarction in the Department of Veterans Affairs Health System. Arch Intern Med 2006; 166:1410–1416.
Zakaria A, Piper M, Douda L, Jackson NM, Flynn JC, Misra DP, et al. Determinants of all-cause in-hospital mortality among patients who presented with COVID-19 to a community teaching hospital in Michigan. Heliyon 2021; 7:e08566.
Solano-López J, Zamorano JL, Sanz AP, Amat-Santos I, Sarnago F, Ibañes EG, et al. Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak. Rev Esp Cardiol 2020; 73:985–993.
Primessnig U, Pieske BM, Sherif M. Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID-19 pandemic. ESC Heart Failure 2021; 8:333–343.
Wu J, Mamas M, Rashid M, Weston C, Hains J, Luescher T, et al. Patient response, treatments, and mortality for acute myocardial infarction during the COVID-19 pandemic. Eur Heart J Qual Care Clin Outcomes 2021; 7:238–246.
Case BC, Yerasi C, Forrestal BJ, Shea C, Rappaport H, Medranda GA, et al. Comparison of characteristics and outcomes of patients with acute myocardial infarction with versus without coronarvirus-19. Am J Cardiol 2021; 144:8–12.
Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol 2020; 13:1–22.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395:1417–1418.
Azevedo RB, Botelho BG, Hollanda JVGD, Ferreira LVL, Junqueira de Andrade LZ, Oei SSML, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens 2021; 35:4–11.
Masi P, Hékimian G, Lejeune M, Chommeloux J, Desnos C, Pineton de Chambrun M, et al. Systemic inflammatory response syndrome is a major contributor to COVID-19–associated coagulopathy: insights from a prospective, single-center cohort study. Circulation 2020; 142:611–614.
De Michele S, Sun Y, Yilmaz MM, Katsyv I, Salvatore M, Dzierba AL, et al. Forty postmortem examinations in COVID-19 patients: two distinct pathologic phenotypes and correlation with clinical and radiologic findings. Am J Clin Pathol 2020; 154:748–760.
Flumignan RL, Civile VT, De Sá Tinôco JD, Pascoal PI, Areias LL, Matar CF, et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev 2022; 3:CD013739.
Spaetgens B, Nagy M, Ten Cate H. Antiplatelet therapy in patients with COVID-19—more is less? JAMA 2022; 327:223–224.
Crudo VL, Ahmed AI, Cowan EL, Shah DJ, Al-Mallah MH, Malahfji M. Acute and subclinical myocardial injury in COVID-19. Methodist Debakey Cardiovasc J 2021; 17:22–30.
Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020; 116:1666–1687.
Cardiology, A. C. O. Clinical Bulletin focuses on cardiac implications of coronavirus (COVID-19 ) [Online]. American College of Cardiology; 2020. https://www.acc.org/latest-in-cardiology/articles/2020/02/13/12/42/acc-clinical-bulletin-focuses-on-cardiac-implications-of-coronavirus-2019-ncov . [Accessed 6 November 2022].